A A E Marcondes1, T G B Gomez1, T T Ravache1, A Batistuzzo1, F B Lorena1,2, C S de Paula1, R Lowenthal3, A C Bianco4, M O Ribeiro5. 1. Developmental Disorders Program, CCBS, Center of Biological Science and Health, Mackenzie Presbyterian University, Rua da Consolação, 930 Bld. #28, São Paulo, SP, 01302-907, Brazil. 2. Federal University of Sao Paulo, São Paulo, Brazil. 3. Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil. 4. Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago, Chicago, IL, USA. 5. Developmental Disorders Program, CCBS, Center of Biological Science and Health, Mackenzie Presbyterian University, Rua da Consolação, 930 Bld. #28, São Paulo, SP, 01302-907, Brazil. miriamribeiro@mackenzie.br.
Abstract
INTRODUCTION: A polymorphism in the type 2 deiodinase (Thr92Ala-DIO2) gene has been associated with behavioral and cognitive dysfunction as well as neurodegeneration and oxidative stress in the central nervous system. OBJECTIVE: To test whether the minor allele (Ala92) frequency (MAF) is increased in children in the autism spectrum disorder (ASD), and whether carriers of the minor allele exhibit more severe symptoms and/or worse adaptive behavior. STUDY DESIGN: ASD children were evaluated at baseline and yearly throughout the study by psychologists using the following tools: autism behavior checklist, Vineland Adaptative Behaviour Scales II, non-verbal intelligence test SON-R 21/2-7, SON-R 6-40, Weschler scale for intelligence, and autism treatment evaluation checklist. SETTINGS: Academic outpatient mental health facility in Sao Paulo, Brazil. PARTICIPANTS: ASD boys and girls younger than 18 years of age. 132 consecutive ASD children, mostly boys (~ 80%); ~ 50% was classified as verbal. Exclusion criteria were coexistence of sensory and/or physical impairment, or any associated genetic syndromes. RESULTS: Median follow-up was for an uninterrupted period of 937 days (139-1375 days), which did not vary significantly among the genotypes. The MAF was 47% in ASD patients vs. 51% in a local reference population with similar ethnic background; the clinical severity and progression were not affected by the minor allele. Carriers of the minor allele exhibited higher adaptive behavior in the domains "daily living skills" and "communication", which correlated positively with the dose of the minor allele. CONCLUSION: The MAF is not different in ASD children, but carriers of the Thr92Ala-DIO2 polymorphism exhibited higher adaptive behavior.
INTRODUCTION: A polymorphism in the type 2 deiodinase (Thr92Ala-DIO2) gene has been associated with behavioral and cognitive dysfunction as well as neurodegeneration and oxidative stress in the central nervous system. OBJECTIVE: To test whether the minor allele (Ala92) frequency (MAF) is increased in children in the autism spectrum disorder (ASD), and whether carriers of the minor allele exhibit more severe symptoms and/or worse adaptive behavior. STUDY DESIGN: ASD children were evaluated at baseline and yearly throughout the study by psychologists using the following tools: autism behavior checklist, Vineland Adaptative Behaviour Scales II, non-verbal intelligence test SON-R 21/2-7, SON-R 6-40, Weschler scale for intelligence, and autism treatment evaluation checklist. SETTINGS: Academic outpatient mental health facility in Sao Paulo, Brazil. PARTICIPANTS: ASD boys and girls younger than 18 years of age. 132 consecutive ASD children, mostly boys (~ 80%); ~ 50% was classified as verbal. Exclusion criteria were coexistence of sensory and/or physical impairment, or any associated genetic syndromes. RESULTS: Median follow-up was for an uninterrupted period of 937 days (139-1375 days), which did not vary significantly among the genotypes. The MAF was 47% in ASD patients vs. 51% in a local reference population with similar ethnic background; the clinical severity and progression were not affected by the minor allele. Carriers of the minor allele exhibited higher adaptive behavior in the domains "daily living skills" and "communication", which correlated positively with the dose of the minor allele. CONCLUSION: The MAF is not different in ASD children, but carriers of the Thr92Ala-DIO2 polymorphism exhibited higher adaptive behavior.
Authors: Elizabeth A McAninch; Sungro Jo; Nailliw Z Preite; Erzsébet Farkas; Petra Mohácsik; Csaba Fekete; Péter Egri; Balázs Gereben; Yan Li; Youping Deng; Mary-Elizabeth Patti; Chantal Zevenbergen; Robin P Peeters; Deborah C Mash; Antonio C Bianco Journal: J Clin Endocrinol Metab Date: 2015-01-08 Impact factor: 5.958
Authors: Maria Davidsson; Nicklas Hult; Carina Gillberg; Charlotte Särneö; Christopher Gillberg; Eva Billstedt Journal: Nord J Psychiatry Date: 2017-08-24 Impact factor: 2.202
Authors: Daniela Mentuccia; Matthew J Thomas; Giuseppe Coppotelli; Laurie J Reinhart; Braxton D Mitchell; Alan R Shuldiner; Francesco S Celi Journal: Thyroid Date: 2005-11 Impact factor: 6.568
Authors: Elizabeth A McAninch; Kumar B Rajan; Denis A Evans; Sungro Jo; Layal Chaker; Robin P Peeters; David A Bennett; Deborah C Mash; Antonio C Bianco Journal: J Clin Endocrinol Metab Date: 2018-05-01 Impact factor: 5.958
Authors: Beatriz C G Freitas; Balázs Gereben; Melany Castillo; Imre Kalló; Anikó Zeöld; Péter Egri; Zsolt Liposits; Ann Marie Zavacki; Rui M B Maciel; Sungro Jo; Praful Singru; Edith Sanchez; Ronald M Lechan; Antonio C Bianco Journal: J Clin Invest Date: 2010-05-10 Impact factor: 14.808
Authors: Shreyas Mahapatra; David Vyshedsky; Samantha Martinez; Benjamin Kannel; Julia Braverman; Stephen M Edelson; Andrey Vyshedskiy Journal: Children (Basel) Date: 2018-02-16
Authors: Wallace Klein Schwengber; Vitor Bock Silveira; Guilherme Moreira Hetzel; Amanda Robaina; Lucieli Ceolin; Marli Teresinha Camelier; Iuri Goemann; Roberta Rigo Dalla Corte; Rafael Selbach Scheffel; Renato Gorga Bandeira de Mello; Ana Luiza Maia; José Miguel Dora Journal: Metabolites Date: 2022-04-21